Richard Charles Woodman Net Worth

Insiders trading at Onconova Therapeutics Inc

Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 és Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.

What does Onconova Therapeutics Inc do?

onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

Onconova Therapeutics Inc executives and stock owners

Onconova Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Steven M. Fruchtman,
  CEO, Pres & Director
• Manoj Maniar,
  Senior Vice President - Product Development
• Mark Patrick Guerin CPA,
  Chief Financial Officer
• Terri Shoemaker,
  Director
• James Marino,
  Chairman of the Board
• Anne VanLent,
  Director
• Jack Stover,
  Director
• Viren Mehta,
  Director
• Jerome Groopman,
  Director
• Henry Bienen,
  Director
• Abraham Oler,
  Vice President, Corporate Development and General Counsel
• Mark Guerin,
  Chief Financial Officer
• Steven Fruchtman,
  President, Chief Executive Officer, Director
• Dr. Ramesh Kumar Ph.D.,
  Advisor
• Dr. Mark Stephen Gelder,
  Chief Medical Officer
• Abraham N. Oler J.D., M.B.A., Esq., CFA,
  Sr. VP of Corp. Devel. & Gen. Counsel
• Capital Management, Llc683 ...,
  
• Capital Management, Llc683 ...,
  
• Ramesh Kumar,
  President and CEO
• Michael B Hoffman,
  Director
• E Premkumar Reddy,
  Director
• Capital Partners L P Tyndall,
  10% owner
• Richard Charles Woodman,
  Chief Medical Officer
• Capital Management, Llc 683,
  10% owner
• Healthcare Sa Baxter,
  10% owner
• Ajay Bansal,
  Chief Financial Officer
• Thomas J Mckearn,
  President, R&D
• & Jane Hoffman 2013 Descend...,
  10% owner
• James Altland,
  SVP, Finance & Corp. Develop.
• Healthcare Sabaxter Interna...,
  
• Capital, Llc Armistice Capi...,
  
• Mary Teresa Shoemaker,
  
• Victor M Moyo,
  CHIEF MEDICAL OFFICER
• Mark S. Md Gelder,
  CHIEF MEDICAL OFFICER
• Peter Atadja,
  
• Trafford Clarke,